Ocugen, Inc.
NASDAQ: OCGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shankar Musunuri
- Employees
- 95
- Headquarters
- Malvern, United States
- IPO year
- 2014
- Market cap
- $470.5M
- Website
- https://www.ocugen.com
Loading OCGN…
Loading profile data…Frequently asked questions about OCGN
What does Ocugen, Inc. (OCGN) do?
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and...
Where does OCGN trade?
Ocugen, Inc. (OCGN) trades on the NASDAQ Capital Market.
What sector is OCGN in?
Ocugen, Inc. (OCGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ocugen, Inc.?
Shankar Musunuri is the chief executive officer of Ocugen, Inc. (OCGN).
Where is Ocugen, Inc. headquartered?
Ocugen, Inc. is headquartered in United States.
Does OCGN pay a dividend?
Ocugen, Inc. (OCGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OCGN go public?
Ocugen, Inc. (OCGN) completed its initial public offering in 2014.